News IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 12:23:52 2026-04-17 pm EDT			5-day change	1st Jan Change
593.41 ^USD	+4.12%		+5.51%	-12.20%

Apr. 15	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
Apr. 14	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT

All News

Apr. 15	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
Apr. 14	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT
Apr. 13	ImmuCell Corporation Announces Board Changes	CI
Apr. 08	IDEXX Laboratories to Release 2026 First Quarter Financial Results	BU
Apr. 01	Idexx Laboratories' Cancer Dx Panel for Canine Lymphoma Early Detection Available in the UK	MT
Apr. 01	Idexx Laboratories, Inc. Announces Uk Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma	CI
Apr. 01	IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma	BU
Mar. 31	Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating	MT
Mar. 26	IDEXX Laboratories, Inc. Announces Departure of Nimrata Hunt as Executive Vice President, Global Strategy and Commercial, Effective April 13, 2026	CI
Mar. 18	Immucell Corporation Announces Changes to Its Board, Effective April 1, 2026	CI
Mar. 02	IDEXX Laboratories, Inc. Presents at 47th Annual Raymond James Institutional Investor Conference, Mar-02-2026 09:15 AM
Mar. 02	IDEXX Laboratories : Raymond James Institutional Investors Conference Presentation	PU
Feb. 26	IDEXX Laboratories, Inc. Presents at BofA Securities Animal Health Summit, Feb-26-2026 09:50 AM
Feb. 24	DENTSPLY SIRONA Inc. Announces Board Changes	CI
Feb. 20	Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.	CI
Feb. 13	IDEXX Laboratories, Inc. Announces Retirement of M. Anne Szostak as Director	CI
Feb. 12	IDEXX Laboratories to Present at Two Institutional Investor Conferences	BU
Feb. 12	Zoetis forecasts strong 2026 profit, revenue on steady pet-medicine demand	RE
Feb. 12	Zoetis forecasts upbeat 2026; pet-care market pressure drags shares	RE
Feb. 12	Zoetis forecasts upbeat 2026; pet-care market pressure drags shares	RE
Feb. 09	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating	MT
Feb. 05	Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating	MT
Feb. 04	Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850	MT
Feb. 04	Piper Sandler Companies Elects Stuart M. Essig to its Board of Directors and Audit Committee, Effective as of February 4, 2026	CI
Feb. 04	Wall Street: When AI Stops Being a Buzzword and Starts Being a Threat